Subtopic Deep Dive
Molecular Profiling of Metastatic Carcinomas
Research Guide
What is Molecular Profiling of Metastatic Carcinomas?
Molecular profiling of metastatic carcinomas uses NGS and gene expression analysis to identify genomic alterations, mutations, fusions, and heterogeneity driving carcinoma metastasis in primary-metastatic tumor pairs.
Researchers apply next-generation sequencing (NGS) to characterize metastasis-specific changes in carcinomas like gastric, breast, and lung cancers. Studies reveal epithelial-mesenchymal transition (EMT) markers in circulating tumor cells (CTCs) and actionable targets for precision oncology. Over 10 papers from 2003-2022, with top-cited works exceeding 1500 citations, focus on gastric cancer guidelines and CTC profiling.
Why It Matters
Molecular profiling identifies HER-2 status for targeted chemotherapy in advanced gastric cancer, improving survival by 6.7 months over best supportive care (Wagner et al., 2017; 1282 citations). CTC analysis detects EMT markers missed by EpCAM-based methods, enabling metastasis biology insights in lung and breast cancers (Gorges et al., 2012; 552 citations; Armstrong et al., 2011; 647 citations). These profiles guide NCCN guidelines for gastric cancer treatment, advancing precision oncology (Ajani et al., 2022; 1575 citations).
Key Research Challenges
Detecting EMT in CTCs
Circulating tumor cells undergoing epithelial-to-mesenchymal transition escape EpCAM-based detection, limiting profiling accuracy in metastatic carcinomas. Gorges et al. (2012) compared protocols showing reduced CTC capture in EMT states. This challenges biomarker development for breast, prostate, and lung cancers.
Primary-Metastatic Heterogeneity
Genomic differences between primary tumors and metastases complicate targeted therapy selection. Armstrong et al. (2011) observed mixed epithelial-mesenchymal markers in prostate and breast CTCs reflecting heterogeneity. Profiling requires paired sample analysis to identify metastasis-specific alterations.
Actionable Mutation Identification
Distinguishing driver mutations from passengers in NGS data for metastatic gastric cancer remains difficult amid high heterogeneity. Wagner et al. (2006) meta-analysis highlighted chemotherapy efficacy but noted gaps in molecular predictors. Guidelines like Ajani et al. (2022) stress HER-2 testing needs broader profiling.
Essential Papers
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histolog...
Epithelial Mesenchymal Transition in Tumor Metastasis
Vivek Mittal · 2018 · Annual Review of Pathology Mechanisms of Disease · 1.5K citations
Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT)...
Chemotherapy for advanced gastric cancer
Dorothea Wagner, Nicholas Syn, Markus Moehler et al. · 2017 · Cochrane Database of Systematic Reviews · 1.3K citations
Chemotherapy improves survival (by an additional 6.7 months) in comparison to BSC, and combination chemotherapy improves survival (by an additional month) compared to single-agent 5-FU. Testing all...
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
Dorothea Wagner, Wilfried Grothe, Johannes Haerting et al. · 2006 · Journal of Clinical Oncology · 1.2K citations
Purpose This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods Randomized phase II and III...
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean et al. · 2011 · Molecular Cancer Research · 647 citations
Abstract During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program....
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Feng‐Hua Wang, Xiao‐Tian Zhang, Yuanfang Li et al. · 2021 · Cancer Communications · 640 citations
Abstract There exist differences in the epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selections between gastric canc...
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
Tobias M. Gorges, Ingeborg Tinhofer, Michael Drosch et al. · 2012 · BMC Cancer · 552 citations
Abstract Background Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs as a biomarker, we c...
Reading Guide
Foundational Papers
Start with Wagner et al. (2006; 1181 citations) for chemotherapy meta-analysis in advanced gastric cancer, then Armstrong et al. (2011; 647 citations) and Gorges et al. (2012; 552 citations) for CTC-EMT profiling basics providing metastasis biology foundations.
Recent Advances
Study Ajani et al. (2022; 1575 citations) NCCN gastric guidelines and Wang et al. (2021; 640 citations) CSCO guidelines for current profiling in precision oncology.
Core Methods
Core techniques: NGS for mutations/fusions, CTC enrichment with epithelial/mesenchymal markers (Armstrong et al., 2011), meta-analysis of chemotherapy outcomes (Wagner et al., 2006), and guideline-integrated HER-2 testing (Ajani et al., 2022).
How PapersFlow Helps You Research Molecular Profiling of Metastatic Carcinomas
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map high-citation works like Ajani et al. (2022; 1575 citations) on gastric cancer guidelines, then findSimilarPapers uncovers related CTC studies such as Gorges et al. (2012). exaSearch queries 'NGS profiling metastatic carcinoma heterogeneity' to retrieve 250M+ OpenAlex papers filtered by citations.
Analyze & Verify
Analysis Agent employs readPaperContent on Armstrong et al. (2011) to extract EMT marker data from CTCs, then verifyResponse with CoVe checks claims against Mittal (2018) for EMT-metastasis links. runPythonAnalysis processes citation counts and survival data via pandas for statistical verification; GRADE grading scores evidence from Wagner et al. (2017) meta-analysis as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in EMT profiling across gastric vs. lung carcinomas, flagging contradictions in CTC detection methods. Writing Agent uses latexEditText and latexSyncCitations to draft LaTeX sections citing Ajani et al. (2022), with latexCompile generating polished reports and exportMermaid visualizing primary-metastatic heterogeneity diagrams.
Use Cases
"Analyze survival data from chemotherapy meta-analyses in metastatic gastric cancer"
Research Agent → searchPapers('Wagner gastric cancer meta-analysis') → Analysis Agent → runPythonAnalysis(pandas on survival months, matplotlib plots) → researcher gets CSV of pooled hazard ratios and forest plots.
"Draft LaTeX review on CTC EMT markers in carcinoma metastasis"
Synthesis Agent → gap detection on Gorges et al. (2012) + Armstrong et al. (2011) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → researcher gets compiled PDF with diagrams.
"Find code for NGS analysis of primary-metastatic tumor pairs"
Research Agent → paperExtractUrls('NGS metastatic carcinoma') → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets repo links with heterogeneity analysis scripts.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ gastric/CTC papers) → citationGraph → GRADE grading → structured report on profiling targets. DeepScan applies 7-step analysis with CoVe checkpoints to verify EMT claims in Mittal (2018) against Wagner et al. (2006). Theorizer generates hypotheses on NGS-detected fusions from Hou et al. (2011) lung CTC data.
Frequently Asked Questions
What is molecular profiling of metastatic carcinomas?
It applies NGS and gene expression to identify mutations, fusions, and heterogeneity in primary vs. metastatic carcinoma pairs, revealing drivers like EMT markers.
What are key methods in this subtopic?
Methods include NGS for genomic alterations, CTC isolation with EMT marker detection beyond EpCAM, and paired tumor profiling as in Armstrong et al. (2011) and Gorges et al. (2012).
What are key papers?
Top papers: Ajani et al. (2022; 1575 citations) on gastric guidelines, Mittal (2018; 1524 citations) on EMT in metastasis, Wagner et al. (2017; 1282 citations) on chemotherapy meta-analysis.
What are open problems?
Challenges include overcoming EMT detection limits in CTCs, resolving primary-metastatic heterogeneity for therapies, and scaling NGS for actionable targets in diverse carcinomas.
Research Metastasis and carcinoma case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Molecular Profiling of Metastatic Carcinomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers